Revvity, Inc. ( (RVTY) ) has released its Q4 earnings. Here is a breakdown of the information Revvity, Inc. presented to its investors.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Revvity, Inc., a company specializing in health science solutions and technologies, operates within the healthcare sector, providing a range of services from discovery to diagnosis. In its recent financial report for the fourth quarter and full year of 2024, Revvity announced a fourth-quarter revenue of $729 million, marking a 5% growth compared to the previous year. The company also reported a GAAP earnings per share (EPS) of $0.78 and an adjusted EPS of $1.42.
During the fourth quarter of 2024, Revvity’s revenue increased to $729 million from $696 million in the same period the previous year. The company also saw a rise in GAAP operating income from $77 million to $119 million, while the adjusted operating income reached $221 million. For the full year, the company reported a GAAP revenue of $2.755 billion, slightly above the previous year’s $2.751 billion, with a GAAP EPS of $2.20.
Segment-wise, the Life Sciences division saw a 5% increase in fourth-quarter revenue, totaling $336 million, while the Diagnostics division reported a 4% rise to $393 million. For the full year, the Diagnostics segment’s revenue increased by 3% to $1.502 billion. The company also initiated its guidance for 2025, forecasting total revenue between $2.80 billion and $2.85 billion, with adjusted EPS expected to range from $4.90 to $5.00.
Looking ahead, Revvity’s management remains optimistic about the future, confident in the company’s ability to leverage its recent transformations and continue its growth trajectory in the coming year.
